PART I Overview We are a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics. We have ongoing Phase 2 clinical studies for our RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF). We developed the worlds first approved self-amplifying messenger RNA (sa-mRNA) vaccine, KOSTAIVE (KOSTAIVE), which we have partnered with Seqirus, Inc. (CSL Seqirus), a part of CSL Limited. KOSTAIV...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001193125-26-088391 | EDGAR | 70K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034787 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031156 | EDGAR | — |
| 2023-03-29 | 2022-12-31 | 0000950170-23-010380 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007832 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009872 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011037 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-275758 | EDGAR | 23K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106560 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0000950170-25-069210 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123469 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0000950170-24-090905 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055702 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063778 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039149 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019773 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023969 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016043 | EDGAR | — |
| 2022-05-09 | 2022-03-31 | 0000950170-22-008524 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-03 | 0001193805-26-000214 | EDGAR | 3K words |
| 2025-12-15 | 0001193805-25-001734 | EDGAR | — |
| 2025-11-10 | 0001193805-25-001555 | EDGAR | — |
| 2025-10-22 | 0001193805-25-001499 | EDGAR | — |
| 2025-09-26 | 0001193805-25-001368 | EDGAR | — |
| 2025-08-29 | 0001193805-25-001247 | EDGAR | — |
| 2025-08-11 | 0001193805-25-001175 | EDGAR | — |
| 2025-06-30 | 0001193805-25-000946 | EDGAR | — |
| 2025-06-06 | 0001193805-25-000820 | EDGAR | — |
| 2025-05-12 | 0001193805-25-000630 | EDGAR | — |
150 total filings indexed. 121 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001768224 |
| Ticker | ARCT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.arcturusrx.com |
| Listed | 2013-05-22 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report